Breast Cancer Clinical Trials
A listing of Breast Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 74 clinical trials
![PILOT STUDY EVALUATING THE UPTAKE OF [18F]F-GLN BY PET/CT IN BREAST CANCER](/media/imagery/6264.svg)
PILOT STUDY EVALUATING THE UPTAKE OF [18F]F-GLN BY PET/CT IN BREAST CANCER
Up to 30 evaluable subjects will participate in a single imaging cohort. Patients will be stratified by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC).Patients who come to the University of Pennsylvania for diagnosis and/or treatment of breast cancer and …
- 0 views
- 19 Feb, 2024
- 1 location
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer
This study will test the experimental drug, ZEN003694, in combination with a marketed drug, talazoparib (Talzenna®), in patients with triple negative breast cancer (TNBC). Among the questions it will seek to answer are: 1. What are well-tolerated doses of ZEN003694 and talazoparib that can be given together without causing significant …
- 0 views
- 19 Feb, 2024
- 1 location
Preoperative use of radiation boost to enhance effectiveness of immune checkpoint blockade therapy in operable breast cancer
Our study is a Phase 1Ib/2 clinical trial to evaluate the safety and feasibility of the combination of radiotherapy (RT) in a single fraction of 7 Gy with pembrolizumab in patients with operable breast cancer. We will employ a Simon Two Stage design to evaluate the safety, feasibility, and efficacy …
- 0 views
- 19 Feb, 2024
- 1 location
A Pilot Study of Risk-Guided Cardioprotection with Carvedilol in Breast Cancer Patients Treated with Doxorubicin and/or Trastuzumab
Subjects with breast cancer starting treatment with anthracyclines/trastuzumab will be enrolled and their risk of cardiotoxicity calculated. If elevated risk, they will be randomized to intervention with carvedilol for 1 year vs usual care.
- 0 views
- 19 Feb, 2024
- 1 location
- 0 views
- 19 Feb, 2024
- 1 location
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 07117: A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Request for collaborative review: WIRB serving as IRB of record.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 13118: Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant Palbociclib and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
To evaluate progression-free survival (PFS) using traditional RECIST critiera with the combination of fulvestrant and palbociclib vs. fulvestrant alone in patients with advanced HR+/HER2- breast cancer that has progressed despite prior CDK4/6 inhibition and endocrine therapy.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 09118:A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
This study will evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in one of the other genes that function with BRCA1 and BRCA2 to repair damaged DNA.
- 0 views
- 19 Feb, 2024
- 1 location